Coherus BioSciences CHRS Stock
Coherus BioSciences Price Chart
Coherus BioSciences CHRS Financial and Trading Overview
| Coherus BioSciences stock price | 1.03 USD |
| Previous Close | 5.36 USD |
| Open | 5.36 USD |
| Bid | 0 USD x 1400 |
| Ask | 0 USD x 1200 |
| Day's Range | 4.85 - 5.45 USD |
| 52 Week Range | 3.6 - 14.11 USD |
| Volume | 6.81M USD |
| Avg. Volume | 2.13M USD |
| Market Cap | 507.11M USD |
| Beta (5Y Monthly) | 0.942605 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0.25 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.75 USD |
CHRS Valuation Measures
| Enterprise Value | 785.96M USD |
| Trailing P/E | N/A |
| Forward P/E | 6.7374997 |
| PEG Ratio (5 yr expected) | 0.12 |
| Price/Sales (ttm) | 2.7655954 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 4.286 |
| Enterprise Value/EBITDA | -3.346 |
Trading Information
Coherus BioSciences Stock Price History
| Beta (5Y Monthly) | 0.942605 |
| 52-Week Change | -14.44% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 14.11 USD |
| 52 Week Low | 3.6 USD |
| 50-Day Moving Average | 6.22 USD |
| 200-Day Moving Average | 7.62 USD |
CHRS Share Statistics
| Avg. Volume (3 month) | 2.13M USD |
| Avg. Daily Volume (10-Days) | 3.64M USD |
| Shares Outstanding | 94.08M |
| Float | 67.91M |
| Short Ratio | 4.34 |
| % Held by Insiders | 1.88% |
| % Held by Institutions | 103.23% |
| Shares Short | 13.01M |
| Short % of Float | 17.21% |
| Short % of Shares Outstanding | 13.83% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -148.012% |
| Operating Margin (ttm) | -130.23% |
| Gross Margin | -51.036% |
| EBITDA Margin | -128.11% |
Management Effectiveness
| Return on Assets (ttm) | -29.97% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 183.36M USD |
| Revenue Per Share (ttm) | 2.35 USD |
| Quarterly Revenue Growth (yoy) | -46.00000000000000000000000000000000% |
| Gross Profit (ttm) | -58399000 USD |
| EBITDA | -234919008 USD |
| Net Income Avi to Common (ttm) | -271399008 USD |
| Diluted EPS (ttm) | -3.49 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 128.09M USD |
| Total Cash Per Share (mrq) | 1.59 USD |
| Total Debt (mrq) | 479.86M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.56 |
| Book Value Per Share (mrq) | -2.441 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -255811008 USD |
| Levered Free Cash Flow (ttm) | -149084624 USD |
Profile of Coherus BioSciences
| Country | United States |
| State | CA |
| City | Redwood City |
| Address | 333 Twin Dolphin Drive |
| ZIP | 94065 |
| Phone | 650 649 3530 |
| Website | https://www.coherus.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 307 |
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Q&A For Coherus BioSciences Stock
What is a current CHRS stock price?
Coherus BioSciences CHRS stock price today per share is 1.03 USD.
How to purchase Coherus BioSciences stock?
You can buy CHRS shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Coherus BioSciences?
The stock symbol or ticker of Coherus BioSciences is CHRS.
Which industry does the Coherus BioSciences company belong to?
The Coherus BioSciences industry is Biotechnology.
How many shares does Coherus BioSciences have in circulation?
The max supply of Coherus BioSciences shares is 115.9M.
What is Coherus BioSciences Price to Earnings Ratio (PE Ratio)?
Coherus BioSciences PE Ratio is 4.12000000 now.
What was Coherus BioSciences earnings per share over the trailing 12 months (TTM)?
Coherus BioSciences EPS is 0.25 USD over the trailing 12 months.
Which sector does the Coherus BioSciences company belong to?
The Coherus BioSciences sector is Healthcare.
Coherus BioSciences CHRS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Composite Total Return I XCMP | 21278.67 USD — |
+1.26
|
— — | 20945.45 USD — | 21305.05 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
| NASDAQ Biotechnology Total Retu XNBI | 4470.08 USD — |
-1.41
|
— — | 4446.23 USD — | 4506.67 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}